candesartan cilexetil has been researched along with Diabetes Mellitus, Adult-Onset in 26 studies
candesartan cilexetil: a prodrug which is metabolized to an active form candesartan to exert its biological effects
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the efficacy and safety of combination therapy with candesartan cilexetil (CC) and pioglitazone hydrochloride (PIO) in patients with hypertension and type 2 diabetes mellitus." | 9.15 | Efficacy and safety of combination therapy with candesartan cilexetil and pioglitazone hydrochloride in patients with hypertension and type 2 diabetes mellitus. ( Enya, K; Kaku, K; Sugiura, K; Totsuka, N, 2011) |
| "CHILI T2D was a non-interventional, open-label, non-controlled, multicentre study in clinical practice that evaluated 4110 patients with type 2 diabetes, uncontrolled hypertension and microalbuminuria who were being prescribed a fixed-dose combination of candesartan cilexetil 16 mg/HCTZ 12." | 9.14 | Candesartan cilexetil/hydrochlorothiazide treatment in high-risk patients with type 2 diabetes mellitus and microalbuminuria: the CHILI T2D study. ( Bramlage, P; Ketelhut, R, 2010) |
| "We aimed to determine whether acute treatment with candesartan cilexetil (CV-11974), an angiotensin II type 1 receptor blocker (ARB) can improve insulin sensitivity in high-fructose-diet (HFD)-fed rats." | 7.78 | Acute treatment with candesartan cilexetil, an angiotensin II type 1 receptor blocker, improves insulin sensitivity in high-fructose-diet-fed rats. ( Jiang, HY; Kawata, Y; Koike, T; Li, P; Oshida, Y; Wang, ZH, 2012) |
| "To investigate the relation between cardiovascular events and blood pressure or blood glucose control during long-term treatment with candesartan cilexetil in Japanese patients with hypertension and diabetes mellitus." | 7.75 | Relation between cardiovascular complications and blood pressure/blood glucose control in diabetic patients with hypertension receiving long-term candesartan cilexetil therapy: Challenge-DM study. ( Fujita, T; Kawamori, R; Matsuoka, H; Saito, Y; Umemura, S, 2009) |
| "Candesartan cilexetil is an effective antihypertensive agent with a tolerability profile similar to that of placebo." | 6.41 | Candesartan cilexetil: an update of its use in essential hypertension. ( Easthope, SE; Jarvis, B, 2002) |
| "Candesartan cilexetil treatment improved cardiac structural remodeling and cardiac function in SDT rats." | 5.35 | Long-term angiotensin II blockade may improve not only hyperglycemia but also age-associated cardiac fibrosis. ( Fukumoto, M; Hayashi, T; Ikeda, T; Jin, D; Kitaura, Y; Miyazaki, M; Oku, H; Sugiyama, T; Takai, S, 2009) |
| "To evaluate the efficacy and safety of combination therapy with candesartan cilexetil (CC) and pioglitazone hydrochloride (PIO) in patients with hypertension and type 2 diabetes mellitus." | 5.15 | Efficacy and safety of combination therapy with candesartan cilexetil and pioglitazone hydrochloride in patients with hypertension and type 2 diabetes mellitus. ( Enya, K; Kaku, K; Sugiura, K; Totsuka, N, 2011) |
| "CHILI T2D was a non-interventional, open-label, non-controlled, multicentre study in clinical practice that evaluated 4110 patients with type 2 diabetes, uncontrolled hypertension and microalbuminuria who were being prescribed a fixed-dose combination of candesartan cilexetil 16 mg/HCTZ 12." | 5.14 | Candesartan cilexetil/hydrochlorothiazide treatment in high-risk patients with type 2 diabetes mellitus and microalbuminuria: the CHILI T2D study. ( Bramlage, P; Ketelhut, R, 2010) |
| "The effect of the angiotensin II receptor blocker, candesartan cilexetil, on proteinuria was examined in a prospective, multicenter, randomized, double-blind study in Japanese subjects with type 2 diabetes." | 5.11 | Antiproteinuric effect of candesartan cilexetil in Japanese subjects with type 2 diabetes and nephropathy. ( Haneda, M; Kawamori, R; Kikkawa, R; Sakai, H, 2004) |
| "We aimed to determine whether acute treatment with candesartan cilexetil (CV-11974), an angiotensin II type 1 receptor blocker (ARB) can improve insulin sensitivity in high-fructose-diet (HFD)-fed rats." | 3.78 | Acute treatment with candesartan cilexetil, an angiotensin II type 1 receptor blocker, improves insulin sensitivity in high-fructose-diet-fed rats. ( Jiang, HY; Kawata, Y; Koike, T; Li, P; Oshida, Y; Wang, ZH, 2012) |
| "To investigate the relation between cardiovascular events and blood pressure or blood glucose control during long-term treatment with candesartan cilexetil in Japanese patients with hypertension and diabetes mellitus." | 3.75 | Relation between cardiovascular complications and blood pressure/blood glucose control in diabetic patients with hypertension receiving long-term candesartan cilexetil therapy: Challenge-DM study. ( Fujita, T; Kawamori, R; Matsuoka, H; Saito, Y; Umemura, S, 2009) |
| " After a 4-week wash-out period, 209 patients were randomized to either CC 8 mg or AML 5 mg once daily for a minimum of 1 month, after which, if BP was not normalized, the dosage was doubled, followed by the addition of hydrochlorothiazide 12." | 2.74 | Effects of candesartan cilexetil on carotid remodeling in hypertensive diabetic patients: the MITEC study. ( Asmar, R; Baguet, JP; Mallion, JM; Nisse-Durgeat, S; Valensi, P, 2009) |
| "Fifty-two patients with type 2 diabetes with normo- and microalbuminuria participated in this study." | 2.71 | Low-dose candesartan cilexetil prevents early kidney damage in type 2 diabetic patients with mildly elevated blood pressure. ( Adachi, M; Hirano, T; Ikejiri, R; Murayama, S; Okada, K; Sakaue, T, 2003) |
| "Many patients with diabetic nephropathy (DN) have levels of albuminuria > 1 g/day and blood pressure >135/85 mmHg, despite antihypertensive combination therapy, including recommended doses of ACE inhibitors, e." | 2.70 | Dual blockade of the renin-angiotensin system in diabetic nephropathy: a randomized double-blind crossover study. ( Christensen, PK; Jensen, BR; Parving, HH; Rossing, K, 2002) |
| "Candesartan cilexetil is an effective antihypertensive agent with a tolerability profile similar to that of placebo." | 2.41 | Candesartan cilexetil: an update of its use in essential hypertension. ( Easthope, SE; Jarvis, B, 2002) |
| "Many models of diabetic nephropathy have been reported." | 1.38 | A novel diabetes mellitus mouse model, MAFA-deficient and beta cell-specific MAFK-overexpressing hybrid transgenic mice, developed severe diabetic nephropathy and improved with TCV-116 (candesartan cilexetil) treatment. ( Fujita, A; Morito, N; Ojima, M; Okamura, M; Shimohata, H; Takahashi, S; Yamagata, K; Yoh, K, 2012) |
| "Candesartan cilexetil treatment improved cardiac structural remodeling and cardiac function in SDT rats." | 1.35 | Long-term angiotensin II blockade may improve not only hyperglycemia but also age-associated cardiac fibrosis. ( Fukumoto, M; Hayashi, T; Ikeda, T; Jin, D; Kitaura, Y; Miyazaki, M; Oku, H; Sugiyama, T; Takai, S, 2009) |
| "We randomized db/db mice, a model of type 2 diabetes with obesity, at the age of 8 weeks to receive candesartan, an ARB, for 6 weeks." | 1.33 | Beneficial effects of candesartan, an angiotensin II type 1 receptor blocker, on beta-cell function and morphology in db/db mice. ( Hirose, T; Ikeda, F; Iwashita, N; Kawamori, R; Ogihara, T; Shao, J; Shimizu, T; Uchida, T; Uchino, H; Watada, H, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (15.38) | 18.2507 |
| 2000's | 16 (61.54) | 29.6817 |
| 2010's | 6 (23.08) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nishida, Y | 1 |
| Takahashi, Y | 1 |
| Susa, N | 1 |
| Kanou, N | 1 |
| Nakayama, T | 1 |
| Asai, S | 1 |
| Kang, MK | 1 |
| Chung, WB | 1 |
| Hong, SK | 1 |
| Kim, OR | 1 |
| Ihm, SH | 1 |
| Chang, K | 1 |
| Seung, KB | 1 |
| Kawamori, R | 4 |
| Fujita, T | 1 |
| Matsuoka, H | 1 |
| Umemura, S | 1 |
| Saito, Y | 1 |
| Jin, D | 1 |
| Takai, S | 1 |
| Sugiyama, T | 2 |
| Hayashi, T | 1 |
| Fukumoto, M | 1 |
| Oku, H | 2 |
| Kitaura, Y | 1 |
| Ikeda, T | 2 |
| Miyazaki, M | 1 |
| Baguet, JP | 1 |
| Asmar, R | 1 |
| Valensi, P | 1 |
| Nisse-Durgeat, S | 1 |
| Mallion, JM | 1 |
| Ketelhut, R | 1 |
| Bramlage, P | 1 |
| Kaku, K | 1 |
| Enya, K | 1 |
| Sugiura, K | 1 |
| Totsuka, N | 1 |
| Fujita, A | 1 |
| Yoh, K | 1 |
| Shimohata, H | 1 |
| Morito, N | 1 |
| Ojima, M | 1 |
| Okamura, M | 1 |
| Takahashi, S | 1 |
| Yamagata, K | 1 |
| Li, P | 1 |
| Koike, T | 1 |
| Jiang, HY | 1 |
| Wang, ZH | 1 |
| Kawata, Y | 1 |
| Oshida, Y | 1 |
| Murayama, S | 1 |
| Hirano, T | 1 |
| Sakaue, T | 1 |
| Okada, K | 1 |
| Ikejiri, R | 1 |
| Adachi, M | 1 |
| Haneda, M | 1 |
| Kikkawa, R | 1 |
| Sakai, H | 1 |
| Malik, RA | 1 |
| Schofield, IJ | 1 |
| Izzard, A | 1 |
| Austin, C | 1 |
| Bermann, G | 1 |
| Heagerty, AM | 1 |
| Rosei, EA | 2 |
| Rizzoni, D | 2 |
| Muiesan, ML | 2 |
| Sleiman, I | 2 |
| Salvetti, M | 2 |
| Monteduro, C | 1 |
| Porteri, E | 2 |
| De Ciuceis, C | 1 |
| Rodella, L | 1 |
| Rezzani, R | 1 |
| Paiardi, S | 1 |
| Bianchi, R | 1 |
| Ruggeri, G | 1 |
| Boari, GE | 1 |
| Zani, F | 1 |
| Miclini, M | 1 |
| Shao, J | 1 |
| Iwashita, N | 2 |
| Ikeda, F | 1 |
| Ogihara, T | 1 |
| Uchida, T | 1 |
| Shimizu, T | 1 |
| Uchino, H | 1 |
| Hirose, T | 1 |
| Watada, H | 2 |
| Sasaki, H | 1 |
| Kanai, S | 1 |
| Oyama, T | 1 |
| Miyashita, Y | 1 |
| Yamamura, S | 1 |
| Shirai, K | 1 |
| Shao, JQ | 1 |
| Du, H | 1 |
| Wang, YY | 1 |
| Zhao, M | 1 |
| Wang, J | 1 |
| Okuno, T | 1 |
| Fukuhara, M | 1 |
| Obayashi, H | 1 |
| Ohta, M | 3 |
| Fukui, M | 1 |
| Hasegawa, G | 1 |
| Nakamura, N | 1 |
| Shibouta, Y | 2 |
| Chatani, F | 1 |
| Ishimura, Y | 1 |
| Sanada, T | 1 |
| Inada, Y | 1 |
| Nishikawa, K | 1 |
| Trenkwalder, P | 3 |
| Lehtovirta, M | 2 |
| Dahl, K | 2 |
| Mulder, H | 1 |
| Noda, M | 1 |
| Matsuo, T | 1 |
| Nagano-Tsuge, H | 1 |
| Sekiguchi, M | 1 |
| Naka, T | 1 |
| Imura, Y | 1 |
| Christensen, PK | 2 |
| Lund, S | 1 |
| Parving, HH | 2 |
| Rossing, K | 1 |
| Jensen, BR | 1 |
| Easthope, SE | 1 |
| Jarvis, B | 1 |
1 review available for candesartan cilexetil and Diabetes Mellitus, Adult-Onset
| Article | Year |
|---|---|
Candesartan cilexetil: an update of its use in essential hypertension.
Topics: Adsorption; Age Factors; Aged; Angiotensin II; Antihypertensive Agents; Benzimidazoles; Biphenyl Com | 2002 |
14 trials available for candesartan cilexetil and Diabetes Mellitus, Adult-Onset
| Article | Year |
|---|---|
Effects of candesartan cilexetil on carotid remodeling in hypertensive diabetic patients: the MITEC study.
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; | 2009 |
Candesartan cilexetil/hydrochlorothiazide treatment in high-risk patients with type 2 diabetes mellitus and microalbuminuria: the CHILI T2D study.
Topics: Aged; Albuminuria; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Diab | 2010 |
Efficacy and safety of combination therapy with candesartan cilexetil and pioglitazone hydrochloride in patients with hypertension and type 2 diabetes mellitus.
Topics: Aged; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Diabetes Complica | 2011 |
Low-dose candesartan cilexetil prevents early kidney damage in type 2 diabetic patients with mildly elevated blood pressure.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphe | 2003 |
Antiproteinuric effect of candesartan cilexetil in Japanese subjects with type 2 diabetes and nephropathy.
Topics: Angiotensin Receptor Antagonists; Benzimidazoles; Biphenyl Compounds; Creatinine; Diabetes Mellitus, | 2004 |
Effects of angiotensin type-1 receptor antagonism on small artery function in patients with type 2 diabetes mellitus.
Topics: Acetylcholine; Adult; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Arteries; Benzimidazo | 2005 |
Effects of candesartan cilexetil and enalapril on inflammatory markers of atherosclerosis in hypertensive patients with non-insulin-dependent diabetes mellitus.
Topics: Adult; Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inh | 2005 |
Effect of treatment with candesartan or enalapril on subcutaneous small artery structure in hypertensive patients with noninsulin-dependent diabetes mellitus.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Arte | 2005 |
Effect of combination therapy of benidipine hydrochloride and candesartan cilexetil on serum lipid metabolism and blood pressure in elderly hypertensive patients with type 2 diabetes mellitus.
Topics: Aged; Aged, 80 and over; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Diabetes Mellitus, Type | 2006 |
Long-term treatment with candesartan cilexetil does not affect glucose homeostasis or serum lipid profile in mild hypertensives with type II diabetes.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood | 1997 |
Antihypertensive treatment with candesartan cilexetil does not affect glucose homeostasis or serum lipid profile in patients with mild hypertension and type II diabetes.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Apolipoproteins; Benzimidazo | 1998 |
Effects of candesartan cilexetil on glucose homeostasis. Multicenter Study Group.
Topics: Aged; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Diabetes Mellitus, Type 2; Double-Blind Me | 1998 |
Autoregulated glomerular filtration rate during candesartan treatment in hypertensive type 2 diabetic patients.
Topics: Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; | 2001 |
Dual blockade of the renin-angiotensin system in diabetic nephropathy: a randomized double-blind crossover study.
Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 2002 |
11 other studies available for candesartan cilexetil and Diabetes Mellitus, Adult-Onset
| Article | Year |
|---|---|
Comparative effect of angiotensin II type I receptor blockers on serum uric acid in hypertensive patients with type 2 diabetes mellitus: a retrospective observational study.
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Biphenyl Compounds; Diabetes Mel | 2013 |
Effects of candesartan cilexetil and amlodipine orotate on receptor for advanced glycation end products expression in the aortic wall of Otsuka Long-Evans Tokushima Fatty (OETFF) type 2 diabetic rats.
Topics: Amlodipine; Animals; Aorta; Benzimidazoles; Biphenyl Compounds; Diabetes Mellitus, Experimental; Dia | 2016 |
Relation between cardiovascular complications and blood pressure/blood glucose control in diabetic patients with hypertension receiving long-term candesartan cilexetil therapy: Challenge-DM study.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood G | 2009 |
Long-term angiotensin II blockade may improve not only hyperglycemia but also age-associated cardiac fibrosis.
Topics: Aging; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; An | 2009 |
A novel diabetes mellitus mouse model, MAFA-deficient and beta cell-specific MAFK-overexpressing hybrid transgenic mice, developed severe diabetic nephropathy and improved with TCV-116 (candesartan cilexetil) treatment.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphe | 2012 |
Acute treatment with candesartan cilexetil, an angiotensin II type 1 receptor blocker, improves insulin sensitivity in high-fructose-diet-fed rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Blood Glucose; | 2012 |
Beneficial effects of candesartan, an angiotensin II type 1 receptor blocker, on beta-cell function and morphology in db/db mice.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Blood Glucose; | 2006 |
[Effects of angiotensin II type 1 receptor blocker on islet of diabetic db/db mice].
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Diabetes Melli | 2007 |
Angiotensin II receptor blocker inhibits abnormal accumulation of advanced glycation end products and retinal damage in a rat model of type 2 diabetes.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Animals; Arginine; Benzim | 2007 |
TCV-116 inhibits renal interstitial and glomerular injury in glomerulosclerotic rats.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl | 1996 |
Involvement of angiotensin II in progression of renal injury in rats with genetic non-insulin-dependent diabetes mellitus (Wistar fatty rats).
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; | 2001 |